Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia

Combining standard cytotoxic chemotherapy with BCR-ABL1 tyrosine kinase inhibitors (TKI) has greatly improved the upfront treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). However, due to the development of drug resistance through both BCR-ABL1-dep...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer research (Chicago, Ill.) Ill.), 2018-10, Vol.78 (20), p.5793-5807
Hauptverfasser:	Minieri, Valentina, De Dominici, Marco, Porazzi, Patrizia, Mariani, Samanta A, Spinelli, Orietta, Rambaldi, Alessandro, Peterson, Luke F, Porcu, Pierluigi, Nevalainen, Marja T, Calabretta, Bruno
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Apoptosis Cell Line, Tumor Cell Survival Cytokines Disease Progression Drug Resistance, Neoplasm Fusion Proteins, bcr-abl - metabolism Gene Expression Regulation, Leukemic Gene Silencing Humans Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Mice Molecular Targeted Therapy Myeloid Cell Leukemia Sequence 1 Protein - metabolism Neoplasm Recurrence, Local Neoplasm Transplantation Philadelphia Chromosome Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy Prognosis Protein Kinase Inhibitors - pharmacology Proto-Oncogene Proteins c-bcl-2 - metabolism RNA, Small Interfering - metabolism Signal Transduction STAT5 Transcription Factor - antagonists & inhibitors STAT5 Transcription Factor - genetics STAT5 Transcription Factor - metabolism Tumor Suppressor Proteins - antagonists & inhibitors Tumor Suppressor Proteins - genetics Tumor Suppressor Proteins - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!